Dimerix (ASX:DXB) Short-Term Debt: A$0.03 Mil (As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.24
! 3 Warning Signs
View Full Analysis

What is Dimerix Short-Term Debt?

Dimerix ASX:DXB -5.88% 32 Short-Term Debt is A$0.03 Mil as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Dimerix's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.03 Mil.

Dimerix's quarterly Short-Term Debt declined from Dec. 2024 (A$0.12 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.03 Mil).

Dimerix's annual Short-Term Debt declined from Jun. 2023 (A$5.94 Mil) to Jun. 2024 (A$0.00 Mil) but then stayed the same from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Dimerix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Dimerix Short-Term Debt Related Terms

Dimerix Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Dimerix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix Short-Term Debt Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.05 0.00 5.94 0.00 0.00

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 0.00 0.12 0.00 0.03
ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.03 Mil mean?
Dimerix (ASX:DXB) has a Short-Term Debt of A$0.03 Mil as of Dec. 2025.
Is Dimerix's Short-Term Debt too high?
Dimerix's current Short-Term Debt is A$0.03 Mil. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Short-Term Debt compare to VRTX and REGN?
Dimerix's Short-Term Debt of A$0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Dimerix's current Short-Term Debt is A$0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Short-Term Debt of A$0.03 Mil. The current Short-Term Debt is A$0.03 Mil. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Short-Term Debt is A$0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.24
Price